Loading
A phase 1/2 trial of Allo-QuadCAR01-T in diffuse large B-cell lymphoma and non-Hodgkin lymphoma, run by AvenCell Therapeutics, Inc., now recruiting.
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies is a phase 1/2 interventional study registered as NCT07284433 by AvenCell Therapeutics, Inc., with 178 participants planned, started 2026-01-06 and due to reach its primary completion in 2029-04-27. Interventions recorded: Allo-QuadCAR01-T.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares CD20, CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares CD19, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares CD20, CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Shares CD19, Diffuse large B-cell lymphoma and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/